JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gabbiani, G.
Right arrow Articles by Selye, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gabbiani, G.
Right arrow Articles by Selye, H.
Journal of Pharmacology And Experimental Therapeutics, Vol. 152, Issue 2, 275-281, 1966
Copyright © 1966 by American Society for Pharmacology and Experimental Therapeutics

THROMBOHEMORRHAGIC LESIONS INDUCED BY COMBINED TREATMENT WITH RARE EARTH METALS AND EPINEPHRINE

G. Gabbiani 1, M. L. Jacqmin 1, and H. Selye 1

1 Institut de Médecine et de Chirurgie expérimentales, Universitéde Montréal, Montreal, Canada

Experiments on rats indicate that intravenous administration of any one among 16 rare earth metal trichlorides produces topical thrombohemorrhagic lesions at sites of epinephrine administration. Depending upon dosage and timing, it is possible to produce such lesions either at the epinephrine injection sites alone or in distant organs also, particularly in the kidney. The thrombohemorrhagic lesions produced by ScCl3 plus epinephrine are regularly prevented by pretreatment with alpha adrenergic blocking agents, but not by a series of antihistaminics, antiserotonins or anticoagulants. Apparently, after treatment with rare earth metals, the catecholamine can create local conditions which greatly favor topical thrombus formation even when the clotting of circulating blood is inhibited by an effective anticoagulant such as bishydroxycoumarine.

Accepted on November 17, 1965




This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
G. LAZAR
Stress: From Concept to Modern Immunology
Ann. N.Y. Acad. Sci., June 30, 1998; 851(1): 16 - 18.
[Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics.